Record #20559
The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib
Publisher
Original paper date
Jan 30, 2013
Original DOI
Country
Institution
Division of Hematology/Oncology, Department of Medicine, Virginia Commonwealth University, Department of Neurosurgery, Virginia Commonwealth University, Department of Biochemistry, Virginia Commonwealth University, Department of Molecular and Human Genetics, Virginia Commonwealth University, Massey Cancer Center, Virginia Commonwealth University, Richmond, VA · 6Division of Hematology Oncology, University of Rochester Medical Center and the James P. Wilmot Cancer Center, Rochester, NY, USA
Open access
No
Article type
Notes from Retraction Watch
Girija Dasmahapatra has an ORI finding of research misconduct;
Citation lifecycle
How this paper is being cited
Pre-retraction
62
Same day
1
Post-retraction
19
% post-retraction
23.2%
~10.2 citations/yr before retraction · ~2.5 citations/yr after
— citing papers
Who is still citing this work
Loading…